ILMNILMNHealthcare · Diagnostics & Research

ILMN Stock Forecast: Illumina, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$193
−3.82% on the day

The 21 Wall Street analysts covering Illumina, Inc. hold a median 12-month price target of $273 — +41.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$30.3B
Ticker Nerd rank
95/ 100
Median analyst target
$273
Analysts covering
21
Revenue$1.1B+4.8% y/y
Operating income$209.0M
Net income$134.0M
Free cash flow$251.0M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.8%
1M
−28.0%
YTD
+47.1%
1Y
+61.8%
From 52W high
−34.3%
From 52W low
+68.6%
$114
$294
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Illumina, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
95/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Issuance
95
Value
88
Momentum
86
Revisions
81
Volatility
75
Growth
63
Accruals
45

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (45): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ILMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ILMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26ILMNHigh $365Median $273Low $165

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
10
Buy
7
Hold
4
Sell
$165
Low
$273
Median
$365
High

The green dot is the last close — the median target sits +41.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 18 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
2 Nov 2026CitigroupMaintainsSell$113 → $210
30 Oct 2026Evercore ISI GroupMaintainsOutperform$290 → $275
30 Oct 2026JP MorganMaintainsOverweight$320 → $300
19 Oct 2026Canaccord GenuityMaintainsHold$205 → $300
13 Oct 2026TD CowenMaintainsHold$210 → $270
7 Oct 2026BarclaysMaintainsUnderweight$160 → $200
5 Oct 2026RBC CapitalMaintainsOutperform$230 → $310
1 Oct 2026GuggenheimMaintainsBuy$226 → $305
29 Sept 2026Leerink PartnersMaintainsOutperform$220 → $300
28 Sept 2026Piper SandlerMaintainsOverweight$225 → $305
9 Sept 2026UBSUpgradeBuy$135 → $260
3 Sept 2026Argus ResearchMaintainsBuy$180 → $235
3 Aug 2026Canaccord GenuityMaintainsHold$190 → $205
3 Aug 2026CitigroupMaintainsSell$95 → $113
3 Aug 2026Piper SandlerReiteratesOverweight$200 → $225
31 July 2026BarclaysMaintainsUnderweight$145 → $160
31 July 2026GuggenheimMaintainsBuy$200 → $226
31 July 2026JP MorganMaintainsOverweight$220 → $230
31 July 2026RBC CapitalMaintainsOutperform$170 → $230
31 July 2026StifelMaintainsBuy$155 → $225

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ILMN.

Market Radar

This page is one stock. Monday covers all of them.

ILMN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ILMN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Illumina, Inc. returned +61.8% against +6.9% for the S&P 500, dividends included.

ILMN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26ILMNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ILMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.3%
Analysts raising
18
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
34.2×

Cheaper than 25% of US stocks

Price / sales
6.6×

Cheaper than 16% of US stocks

Price / book
9.6×

Cheaper than 8% of US stocks

EV / EBITDA
27.4×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
4.2%

Higher than 38% of US stocks

Earnings growth (YoY)
46.7%

Higher than 74% of US stocks

Gross margin
66.1%

Higher than 79% of US stocks

Operating margin
19.1%

Higher than 78% of US stocks

Net margin
19.7%

Higher than 81% of US stocks

Returns & dividend
Return on equity
32.4%

Higher than 89% of US stocks

Return on assets
8.3%

Higher than 88% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Illumina, Inc. has a market value of $30.3B and an enterprise value of $31.3B.

  • Revenue in the twelve months to 31 Mar 2026: $4.4B. The latest quarter grew 4.8% year on year.

  • Net income over the same four quarters: $853.0M, a 19.4% net margin.

  • Diluted earnings per share, trailing twelve months: $5.50.

  • Free cash flow in the twelve months to 31 Mar 2026: $967.0M, after $154.0M of capital spending.

  • Illumina, Inc. spent $784.0M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 151.0M.

  • Trailing P/E: 34.2×; forward P/E: 32.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Illumina, Inc. employs 8,600 people — $511K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ILMN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ILMNIllumina, Inc.$30.3B95
DGXQuest Diagnostics, Inc.$28.7B93
LHLabcorp Holdings, Inc.$30.4B88
MTDMettler-Toledo International, Inc.$34.1B96
NTRANatera, Inc.$39.6B70
IQVIQVIA Holdings, Inc.$40.5B83
WATWaters Corp.$43.2B52

Take a look at ILMN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Illumina, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ILMN

What is the ILMN stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Illumina, Inc. have a median 12-month price target of $273, with estimates ranging from $165 to $365. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ILMN stock a buy right now?

Of the 21 analysts covering Illumina, Inc., 10 rate it a Buy, 7 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Illumina, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ILMN?

As at 21 Nov 2026, Illumina, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ILMN stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +41.2% from the last close, and Ticker Nerd's factor model ranks Illumina, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ILMN stock forecast for 2030?

No analyst covering Illumina, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ILMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $365 over the next 12 months.

How has ILMN stock performed over the past year?

Illumina, Inc. returned +61.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Illumina, Inc. do?

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics.

Company

About Illumina, Inc.

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.

CEO Mr. Jacob Thaysen Ph.D. · 8,600 employees · United States · https://www.illumina.com